Arbutus Biopharma Corporation

NasdaqGS:ABUS Stock Report

Market Cap: US$455.9m

Arbutus Biopharma Balance Sheet Health

Financial Health criteria checks 6/6

Arbutus Biopharma has a total shareholder equity of $106.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $144.4M and $38.4M respectively.

Key information

0%

Debt to equity ratio

US$0

Debt

Interest coverage ration/a
CashUS$126.00m
EquityUS$106.02m
Total liabilitiesUS$38.38m
Total assetsUS$144.40m

Recent financial health updates

Recent updates

Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation

Feb 10
Here's Why We're Watching Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Situation

Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Jan 03
Arbutus Biopharma Corporation (NASDAQ:ABUS) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected

Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week

Nov 09
Analysts Are Betting On Arbutus Biopharma Corporation (NASDAQ:ABUS) With A Big Upgrade This Week

Some Shareholders Feeling Restless Over Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S Ratio

Oct 24
Some Shareholders Feeling Restless Over Arbutus Biopharma Corporation's (NASDAQ:ABUS) P/S Ratio

We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow

Apr 26
We're Interested To See How Arbutus Biopharma (NASDAQ:ABUS) Uses Its Cash Hoard To Grow

Broker Revenue Forecasts For Arbutus Biopharma Corporation (NASDAQ:ABUS) Are Surging Higher

Nov 11
Broker Revenue Forecasts For Arbutus Biopharma Corporation (NASDAQ:ABUS) Are Surging Higher

We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth

Oct 28
We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth

Arbutus Biopharma: Our Current Take On This 2 Buck 'Soap Opera'

Sep 12

Arbutus stock rises on US patent linked to hepatitis B therapy AB-729

Aug 30

Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts

Aug 06
Brokers Are Upgrading Their Views On Arbutus Biopharma Corporation (NASDAQ:ABUS) With These New Forecasts

Arbutus Biopharma, Assembly Biosciences plan to continue their hepatitis B mid-stage trial

Jul 20

Arbutus: 2 Key Catalysts To Look Forward To After EASL Data Release

Jun 29

We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth

Jun 15
We Think Arbutus Biopharma (NASDAQ:ABUS) Can Easily Afford To Drive Business Growth

Rainbows and Unicorns: Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Just Became A Lot More Optimistic

May 11
Rainbows and Unicorns: Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Just Became A Lot More Optimistic

Need To Know: Analysts Are Much More Bullish On Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenues

Mar 08
Need To Know: Analysts Are Much More Bullish On Arbutus Biopharma Corporation (NASDAQ:ABUS) Revenues

Arbutus Biopharma; Long-Term Hold With Advancements Into Several Areas Of Interest

Mar 07

Arbutus Biopharma: How Will Patent Win Impact Stock Outlook?

Dec 17

Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans

Dec 14
Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans

Arbutus Biopharma: Recent Acquisition Of Dicerna Makes It An Attractive Investment

Nov 20

Arbutus Biopharma: A First Assessment

Sep 15

We're Keeping An Eye On Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate

Sep 11
We're Keeping An Eye On Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate

Arbutus' Recent Hepatitis B Data At EASL 2021 Makes The Case For A Great Long-Term Investment

Jun 29

Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans

May 21
Arbutus Biopharma (NASDAQ:ABUS) Is In A Good Position To Deliver On Growth Plans

Arbutus Bio slips 4% as Q1 revenue trails consensus

May 05

What You Need To Know About Arbutus Biopharma Corporation's (NASDAQ:ABUS) Investor Composition

Mar 12
What You Need To Know About Arbutus Biopharma Corporation's (NASDAQ:ABUS) Investor Composition

We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth

Feb 02
We Think Arbutus Biopharma (NASDAQ:ABUS) Can Afford To Drive Business Growth

Arbutus Biopharma's (NASDAQ:ABUS) Stock Price Has Reduced 29% In The Past Three Years

Jan 07
Arbutus Biopharma's (NASDAQ:ABUS) Stock Price Has Reduced 29% In The Past Three Years

Arbutus Biopharma (ABUS) Investor Presentation - Slideshow

Dec 17

What Is The Ownership Structure Like For Arbutus Biopharma Corporation (NASDAQ:ABUS)?

Dec 12
What Is The Ownership Structure Like For Arbutus Biopharma Corporation (NASDAQ:ABUS)?

Financial Position Analysis

Short Term Liabilities: ABUS's short term assets ($132.0M) exceed its short term liabilities ($22.5M).

Long Term Liabilities: ABUS's short term assets ($132.0M) exceed its long term liabilities ($15.9M).


Debt to Equity History and Analysis

Debt Level: ABUS is debt free.

Reducing Debt: ABUS had no debt 5 years ago.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ABUS has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ABUS has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 1% each year.


Discover healthy companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.